Human congestive heart failure is characterized by complex neurohumoral activation associated with the up-regulation of vasoconstricting and salt-retaining mediators and the compensatory rise of counter-regulatory hormones. In the present study, we provide the first evidence that relaxin (RLX), known as a pregnancy hormone, represents a potential compensatory mediator in human heart failure: plasma concentrations of RLX and myocardial expression of the two RLX genes (H1 and H2) correlate with the severity of disease and RLX responds to therapy. The failing human heart is a relevant source of circulating RLX peptides, and myocytes as well as interstitial cells produce RLX. Elevation of ventricular filling pressure up-regulates RLX expression and the hormone acts as a potent inhibitor of endothelin 1, the most powerful vasoconstrictor in heart failure. Furthermore, RLX modulates effects of angiotensin II, another crucial mediator. Our data identify RLX as a new player in human heart failure with potential diagnostic and therapeutic relevance.-Dschietzig, T., Richter, C., Bartsch, C., Laule, M., Armbruster, F. P., Baumann, G., Stangl, K. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 15, 2187-2195 (2001) 
Human congestive heart failure (CHF) is characterized by complex neurohumoral activation associated with the up-regulation of vasoconstricting and saltretaining mediators: catecholamines, angiotensin II (AT-II), endothelin 1 (ET-1), and vasopressin. Neurohumoral activation also entails the compensatory rise of vasodilating and natriuretic mediators: atrial and brain natriuretic peptides as well as adrenomedullin (9) . Until now, neither the possible involvement of RLX in these neuroendocrine alterations nor its expression in the human cardiovascular system had been investigated, although the hormone may represent a novel candidate in view of the above-mentioned cardiovascular actions observed in animal experiments.
In the present study, we present clinical and experimental data that elucidate the role of RLX as a player in human heart failure.
MATERIALS AND METHODS

Patients and protocol
To avoid possible bias of RLX data by different phases of the menstrual cycle, only postmenopausal women that had ceased menstruating for at least 12 months were enrolled. Enrollment of patients took place according to the following study design.
Group 1: severe CHF
Fourteen CHF patients in functional class NYHA IV were enrolled (five females, nine males; mean ageϮsd, 58Ϯ7 years, mean left ventricular ejection fraction [LVEF]Ϯsd, 19Ϯ3%). Seven patients suffered from CHF secondary to ischemic heart disease (IHD) and seven demonstrated dilated cardiomyopathy (DCM). Inclusion criteria were:
1) Need for intensive care treatment for acute left heart decompensation (orthopnea, signs of severe pulmonary congestion). Acute ischemia was excluded on the basis of electrocardiography, as well as kinetics of enzymes (troponins, creatin kinase) and myoglobin.
2) PCWP Ͼ 25 mmHg, CI Ͻ 2.5 l/min/m 2 .
Group 2: moderate CHF
CHF patients were assigned to the moderate CHF group (nϭ13, four females, nine males; age, 54Ϯ7 years; LVEF, 27Ϯ4%) if they were 1) in NYHA class II and displayed 2) a PCWP Ͻ 20 mmHg and a CI Ͼ 2.5 l/min/m 2 . Individuals were recruited among patients undergoing hemodynamic evaluation before coronary bypass surgery and/or partial ventriculectomy. Six patients suffered from CHF secondary to IHD and seven demonstrated DCM.
We treated Group 1 and 2 patients over 12 h with sodium nitroprusside at a dosage that decreased systemic vascular resistance to 800-1000 dyn/s/cm Ϫ5 without lowering mean arterial blood pressure below 60 mm Hg. Intravenous (i.v.) furosemide was given according to clinical requirements; i.v. nitrates, catecholamines, and phosphodiesterase inhibitors were not administered. All CHF patients were on stable oral therapy: all on ACE inhibitors and diuretics; 18 on nitrates; 15 on ␤-blockers; and 10 on digitalis.
Group 3: controls
Thirteen controls (four females, nine males; age, 55Ϯ4 years; LVEF, 65Ϯ5%) were recruited among individuals who were undergoing cardiac catheterization for suspected coronary artery disease and in whom no structural cardiovascular disease was detected.
Instrumentation and blood sample collection
In all groups, catheters were positioned in the pulmonary artery (PA) (Swan-Ganz), the coronary sinus (CS), and the left ventricle (LV) under fluoroscopic control. Blood sampling and hemodynamic measurements were carried out at baseline in all groups and at 2, 4, 6, and 12 h after initiation of therapy in Groups 1 and 2. In all groups, an additional sample of venous blood was drawn 48 h after initiation of therapy and catheterization. At baseline, arterial blood (A) was simultaneously drawn from LV and from the radial artery to establish comparability of these sites. During treatment, arterial blood was drawn from the radial artery. In addition, blood was taken from PA, CS, and the antecubital vein (V). In Groups 1 and 2, the left ventricular catheter and the CS catheter were removed for safety after baseline measurement and after 4 h, respectively. Arterial and pulmonary arterial catheters were removed 12-14 h after initiation of therapy. MAP during treatment was measured invasively in the radial artery. Heart rate, MAP, and pulmonary arterial pressure (PAP) were continuously monitored and cardiac output (CO) was determined by thermodilution.
Exclusion criteria were renal failure with creatinin level over 250 M, need of i.v. treatment other than SNP and furosemide, severe noncardiovascular systemic diseases, or primary pulmonary hypertension.
This study was approved by the local Ethics Committee and was conducted according to Declaration of Helsinki principles. Before the study, all patients gave their informed, written consent.
Determination of plasma relaxin
RLX was determined by use of a commercial ELISA kit (Immundiagnostik, Bensheim, Germany). The polyclonal antibody was raised in rabbits. The kit had a detection limit of 0.40 pg/ml that was calculated from the mean optical density of the zero standard (measured in duplicate) plus 2 standard deviations. The intra-assay coefficient of variation is 9.6% (nϭ18, at 15 pg/ml) and the interassay coefficient of variation is 10.2% (nϭ12, at 15 pg/ml). The kit is highly selective for human RLX, with cross-reactivity measuring 100% for the H1 form and 100% for the H2 form. Cross-reactivity against insulin, insulin-like growth factors, LH, FSH, and prolactin is less than 0.01%.
Determination of ET-1
ET-1 concentrations in plasma and in supernatant of cultured cells were detected as described elsewhere (10) .
RNA analysis
We determined expression of prepro-RLX and prohormone convertase 1 (PC-1) mRNA. The latter, also referred to as PC-1/3, has been reported to process proRLX (11) . We used the following tissue samples.
Left ventricles
Control samples were human total left ventricular RNA from healthy individuals (nϭ4) (Invitrogen, San Diego, CA) and a sample from one donor heart that was not transplanted. Failing myocardium was from patients with DCM (nϭ5) and IHD (nϭ3) who underwent partial ventriculectomy or transplantation.
Right atria and vessels
Samples from right atrium (nϭ8), mammary artery (nϭ6), and saphenous vein (nϭ6) were obtained from patients with normal heart function; vascular specimens (nϭ4 each) were also taken from CHF patients. All these patients underwent bypass surgery. We used samples from dilated right atria of DCM patients (nϭ4) who underwent partial ventriculectomy. In all patients, heart function had been assessed by preoperative catheterization.
The use of human tissue samples in this study was approved by the local Ethics Committee and was conducted according to Declaration of Helsinki principles. In all cases except for the control left ventricular samples (see above), we had the informed, written consent of the respective patients.
Tissue samples were placed in liquid nitrogen and stored at Ϫ70°C for subsequent RNA isolation. For total RNA isolation according to the method described by Chomczynski and Sacchi (12) , tissues were homogenized, after 20 min incubation at 30°C, in 1.7 ml TRIZOL Reagent (Life Technologies, Gaithersburg, MD) per 50 mg tissue. Extraction of RNA was performed by addition of 0.3 ml chloroform per 1 ml TRIZOL, incubation at 30°C for 3 min, and subsequent centrifugation (12,000 rpm, 30 min, 4°C). RNA in the aqueous phase was precipitated by addition of 0.8 ml isopropyl alcohol per 1 ml TRIZOL. After centrifugation (12,000 rpm, 30 min, 4°C), the pellet obtained was dissolved in diethylpyrocarbonate-treated water.
Total RNA (2 g) was reverse transcribed using avian myeloblastosis virus reverse transcriptase and dT 15 primers according to the manufacturer's instructions (First Strand cDNA Synthesis Kit, Boehringer Mannheim, Mannheim, Germany). PCR amplification of single-stranded cDNA was then performed using primer pairs specific for H1 and H2 prepro-RLX (H1 and H2 5Ј primer: 5Ј TCT GTT TAC TAC TGA ACC AAT TT 3Ј; H1 3Ј primer: 5Ј CTC AAA CAG TGC CAC GTA GGG TCG 3Ј; H2 3Ј primer: 5Ј ATT AGC CAA TGC ACT GTA GAG TTG 3Ј) (TIB MOLBIOL), PC-1 (5Ј primer: 5Ј GTG AAC TGG AAG CTG ATT TTG CAC G 3Ј; 3Ј primer: 5Ј CAT AAG AAT TCA TGA CAA AAC AAC C 3Ј), and for human GAPDH (5Ј primer: 5Ј TGA AGG TCG GAG TCA ACG GAT TTG GT 3Ј; 3Ј primer: 5Ј CAT GTG GGC CAT GAG GTC CAC CAC 3Ј) (Clontech, Palo Alto, CA). The primer sequences for H1 and H2 prepro-RLX were selected according to the work published by Gunnersen and co-workers (13) . The common 5Ј primer is directed against the B chain (bases 35-57 of GenBank accession number E00220/00219). The specific 3Ј primers for H1 (accession E00220) and H2 (accession E00219) bind to the A chain (bases 484 -507).
Southern blot hybridization was conducted for quantitation of the amplified sequences. PCR products were separated on 2% agarose gels, blotted onto nylon membranes (Hybond N, Amersham, Arlington Heights, IL), hybridized using radioactively labeled oligos specific for H1 or H2, and directed against the C peptide (bases 249 -273 of GenBank accessions E00220 and E00219) (H1: 5Ј AAT GAA TTC CAA CAT GAT AAT TAT A 3Ј; H2: 5Ј AAC AAA TTC TGA CAT CAT ATT TAT G 3Ј, sequences according to ref 13) (Easy Hyb, Boehringer Mannheim). Finally, autoradiography was performed and autoradiographs were quantified by use of the ImageMaster 1D Prime software (Pharmacia Biotech, Peapack, NJ). All data were normalized to GAPDH mRNA expression.
Cloning and sequencing of the different RLX mRNA forms
We used the Eukaryotic TA Cloning Kit (pCR 3.1 vector, Invitrogen) and the Standard Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions.
Immunostaining and immunofluorescence
Sections (5 m thick) were cut from paraffin-embedded left ventricular tissues and placed on gelatin-coated glass slides. As primary antibody, we used the polyclonal antibody described for the RLX ELISA. Tissues were incubated with the primary antibody (dilution 1:300) for 24 h (4°C); the secondary goat anti-rabbit antibody and the tertiary reagent were left on the tissues for 1 h at room temperature. We used 3,3Ј-diaminobenzidine tetrachloride as chromogen. In addition, we performed hematoxylin and eosin counterstaining to assign the RLX immunoreactivity to certain cell types.
We used freeze sections (5 m) to detect RLX immunoreactivity in left ventricles, right atria, and vessels. The secondary goat anti-rabbit antibody was labeled with the fluorochrome cyanin-3.
Method specificity was tested by substitution of the primary antibody with serum from a nonimmunized rabbit (dilution 1:300).
Western blot analysis
Tissue samples (50 mg) were lysed at 90°C over 30 min in 100 l diethylpyrocarbonate-treated water plus 100 l SDS buffer (125 mM Tris-Cl, 20% glycerin, 6% SDS, 10% ␤-mercaptoethanol, 0.02% bromphenol blue). The homogenates were centrifuged at 10.000 rpm over 15 min. Ten microliters of the supernatants were separated on a 17.5% SDS-PAGE gel. We then blotted separated proteins to polyvinylidene difluoride membranes (Millipore, Bedford, MA) (300 mA, 1 h). These membranes were blocked over 2 h at room temperature (5% dried milk, 0.05% gelatin, 1% BSA, 0.02% Tween 20, 1ϫ TBS [50 mM Tris, 150 mM NaCl]). Membranes were subsequently incubated overnight at 4°C with the primary antibody (dilution 1:200 for RLX and 1:500 for ␣-actin). As primary antibodies, we used the polyclonal RLX-specific antibody described for the RLX ELISA and a monoclonal mouse anti-actin antibody. After washing twice for 5 min and twice for 15 min with 1ϫ TBS plus 0.02% Tween 20, membranes were incubated over 2 h at room temperature with the secondary antibody (peroxidase-conjugated mouse anti-rabbit or goat anti-mouse IgG). Finally, the immunoreactive bands were visualized with the BM Chemoluminescence system (Boehringer Mannheim).
The exogenous H1 RLX used for the positive controls was generously provided by Dr. J. Wade from the Howard Florey Institute (Melbourne, Australia); H2 RLX was a gift from Dr. W. Voelter (University of Tuebingen).
Experiments in isolated rat hearts
Isolated Langendorff hearts of male Wistar rats (180 -250 g body weight) were perfused over 2 h in constant pressure mode with modified Krebs-Henseleit buffer (37°C; pH 7.35-7.45; composition in mM: NaCl 116, KCl 4.0, MgSO 4 1.2, KH 2 PO 4 1.2, NaHCO 3 25, CaCl 2 2.5, glucose 10, HEPES 6; equilibration with 95% O 2 and 5% CO 2 ). A left ventricular enddiastolic pressure (LVEDP) of either 5 mm Hg (controls) or 25 mm Hg (nϭ3 for each group) was adjusted by means of a fluid-filled latex balloon. In another subset of these experiments (nϭ3 for each group), we adjusted the mean right or left atrial pressure by means of a balloon to either normal (5 mm Hg) or elevated values (25 mm Hg). Subsequently, the respective tissues-free left ventricular or right/left atrial wall-were rapidly frozen in liquid nitrogen and stored at Ϫ70°C for determination of RLX mRNA. We performed total RNA isolation and reverse transcription as described above. PCR was performed using primers for rat prepro-RLX. The 5Ј primer was directed against bases 200 -222 of the sequence published in ref 14 (GenBank accession number V01264) (5Ј GGA AGA CTG GCT TTG AGC CAG GA 3Ј), and the 3Ј primer binds to bases 608 -630 (5Ј CCG GGT TGC GCA CCA TTA GCT CC 3Ј) (TIB MOLBIOL).
Cell culture
Bovine pulmonary artery endothelial cells (CPAE, No. CCL-209, American Type Culture Collection, Rockville, MD), passage 6, were grown in MEM (Life Technologies) supplemented with 1.5 g/l sodium bicarbonate, 0.11 g/l sodium pyruvate, 100 U/ml penicillin, 100 g/ml streptomycin, and 5% FCS in a humidified 5% CO 2 atmosphere. Cells were grown to subconfluence for investigation of the AT-II-induced ET-1 secretion, but were used at complete confluence for the flow chamber experiments. The exogenous H2 RLX used in these experiments was a gift from Dr. W. Voelter (University of Tuebingen).
Flow chamber
The rectangular laminar flow chamber (6.0 cm length, 4.5 cm width) was perfused with a circulating volume of 300 ml cell culture medium gassed with 95% air and 5% carbon dioxide over 16 h. Shear stress (in dyn/cm 2 ) was adjusted according to the following formulas for a Newtonian fluid (15):
(, viscosity in dyn s/cm 2 ; Q, laminar flow in cm 3 /s; B, chamber width in cm; h, chamber height in cm; ⌬p, pressure gradient across the chamber in dyn/cm 2 ; L, chamber length in cm). The flow-induced pressure gradient across the chamber was measured as the difference between inlet and outlet pressure and kept constant for varying values of by adopting the following procedure: to achieve a change from 1 to 2 , we adjusted the chamber height h by 2 / 1 and the flow Q by ( 2 / 1 ) 3 , which yields a constant ⌬p and a linear rise of with h.
Data analysis
Data are presented as mean Ϯ se unless otherwise indicated. An error probability of P Ͻ 0.05 was regarded as significant.
Values for unpaired data (hemodynamic parameters, cell culture experiments) were compared using the Kruskal-Wallis ANOVA on ranks or the Mann-Whitney rank sum test. Differences between groups over time (hemodynamics and peptide levels) were analyzed with a nonparametric ANOVA for repeated measures (16) . In each case, a multiple-comparison procedure with Bonferroni-Holm adjustment of P was carried out after global testing (17) .
Regression analyses were performed using commercial software for linear and nonlinear regression (SigmaStat, Jandel Scientific, Corte Madera, CA).
RESULTS
Plasma RLX in human heart failure and response to acute hemodynamic improvement
We first determined circulating RLX peptide levels as a function of the hemodynamically defined stage of the disease. Patients with moderate CHF exhibited significantly higher systemic and pulmonary vascular resistances than did healthy individuals ( Table 1) . Depending on the sites of measurement (left ventricle, pulmonary artery, coronary sinus, or antecubital vein), plasma levels of RLX in moderate CHF (Fig. 1A) were four-to sixfold higher than those determined in the control patients. Patients with severe CHF were characterized by drastically elevated pulmonary pressures and pulmonary vascular resistance, as well as by markedly lower cardiac index than were patients with moderate CHF (Table 1 ). These patients with severe CHF displayed RLX levels 2.2-to 2.6-fold those of patients with moderate CHF and 12-to 16-fold those detected in controls. To identify hemodynamic determinants of RLX levels, we performed regression analyses demonstrating closest correlations of RLX with left ventricular filling pressure (rϭ0.69, PϽ0.001) and cardiac index (rϭϪ0.62, PϽ0.001).
Eleven of the 14 patients with severe CHF (i.e., 79%) showed higher RLX plasma levels in coronary sinus than in left ventricle (Fig. 1B) . This finding indicates net coronary release of RLX in the majority of patients suffering from severe CHF.
At baseline, simultaneous determination of plasma Figure 1 . In patients, plasma levels of RLX increase with the severity of CHF and respond to acute hemodynamic improvement. Levels of RLX were detected in left ventricle (LV), pulmonary artery (PA), coronary sinus (CS), and antecubital vein (V). Data (meanϮse) are given in pg/ml. Detection limit of the RLX ELISA was 0.40 pg/ml. A) Baseline levels. P Ͻ 0.05; #severe vs. moderate CHF; *severe CHF vs. controls; §moderate CHF vs. controls. B) Eleven of 14 patients with severe CHF (i.e., 79%) revealed coronary net release of RLX, i.e., plasma levels are higher in CS than in LV. C) Course of circulating venous RLX during and after 12 h vasodilator therapy with sodium nitroprusside. P Ͻ 0.05; #vs. baseline.
RLX from the LV and the radial artery proved the reliability of concentrations detected in the radial artery for monitoring the subsequent treatment throughout 12 h [severe CHF: LV, 18.9Ϯ3.4; radial artery; 18.5Ϯ3.9 pg/ml (NS); moderate CHF: LV, 7.9Ϯ1.2; radial artery, 7.6Ϯ1.3 pg/ml (NS)]. We subsequently treated both CHF patient groups for 12 h with the vasodilator sodium nitroprusside. In patients with severe CHF, the treatment induced significant changes in mean arterial pressure (after 2 h: Ϫ23Ϯ2% of baseline values), mean pulmonary arterial pressure (Ϫ39Ϯ3%), pulmonary capillary wedge pressure (Ϫ46Ϯ2%), and systemic (Ϫ65Ϯ5%) and pulmonary (Ϫ52Ϯ3%) vascular resistance. Results for the cardiac index showed a significant increase (ϩ70Ϯ3%). Maximum hemodynamic effects had already been achieved within the first 2 h of treatment. This acute vasodilator therapy evoked a delayed decrease in plasma RLX that was detectable 48 h after initiation of therapy (Fig. 1C) . In patients with moderate CHF, only the decreases in mean arterial pressure (2 h: Ϫ30Ϯ1%) and systemic vascular resistance (3 h: Ϫ53Ϯ3%) were significant. In these patients vs. patients with severe CHF, plasma concentrations of RLX did not change over 48 h.
Increased H1 and H2 gene expression in failing atrial and ventricular tissues
Because RLX gene expression has not until now been described for human cardiovascular tissues, we sought to identify candidate cardiovascular sources of RLX. By RT-PCR, we were able to detect both H1 and H2 mRNA in left ventricles, right atria, mammary arteries, and saphenous veins from patients demonstrating normal heart function (Fig. 2) . These findings suggest constitutive H1 and H2 gene expression in these tissues. Particularly in the vessels, we found a 101 bp larger specific PCR product, which represents the splicing form of H1 and H2 mRNA reported by Gunnersen and co-workers for human placenta and prostate gland (13) . Sequencing of the different PCR products (H1, H2, and the splicing form) verified their specificity.
We next examined whether the occurrence of CHF was accompanied by elevated RLX gene expression in myocardial and vascular tissues compared with the control tissues mentioned above (Fig. 2) . In left ventricular specimens of failing hearts, we determined pronounced up-regulation of GAPDH-normalized H1 mRNA (failing hearts, 14.4Ϯ2.4 vs. nonfailing hearts, 1.0Ϯ0.5 arbitrary units; PϽ0.05) and a moderate increase in H2 mRNA (2.6Ϯ0.4 vs. 1.0Ϯ0.2 units, PϽ0.05). H1 expression was increased moderately in right atria from failing hearts compared with specimens from nonfailing hearts (2.1Ϯ0.4 vs. 1.0Ϯ0.2 units, PϽ0.05). Results for right atrial H2 mRNA also showed a more pronounced elevation in failing hearts (3.8Ϯ1.0 vs. 1. 0Ϯ0.1 units, PϽ0.05) . In contrast, expression of RLX mRNA species apparently did not differ in mammary arteries and saphenous veins from patients with normal heart function and from patients with CHF.
Detection of proRLX protein and gene expression of the processing enzyme
Western blot analysis in right atrial and left ventricular specimens obtained from nonfailing and failing hearts (Fig. 3) revealed a band of the size expected for prorelaxin (ϳ 18 kDa) (11) in all samples. We further proved that exogenous mature H1 and H2 was well recognized in our setting, but tissue levels were obviously below the sensitivity of the method applied. The tissue concentration of prorelaxin (normalized to ␣-actin) was approximately doubled in failing right atria (2.3Ϯ0.3 vs. 1.0Ϯ0.3 arbitrary units), but unchanged in failing left ventricles when compared with control tissues (0.9Ϯ0.1 vs. 1.0Ϯ0.1 units).
Although expression of PC-1 has been observed before only in human neuroendocrine tissues (brain, pituitary and adrenal glands, pancreas) (11, 18) , we clearly detected PC-1 mRNA in nonfailing and failing atrial and ventricular tissues as well as in vessels (Fig. 3 , data only shown for myocardium). Moreover, we were able to show that mRNA expression of the RLXprocessing enzyme is regulated in CHF: the transcript levels are uniformly decreased in failing right atria when compared with nonfailing tissue. In failing left ventricular myocardium, however, we observed a broad range of PC1 mRNA expression; in nonfailing left ventricles, PC1 mRNA was expressed uniformly.
Immunolocalization of RLX in myocardial tissue
Immunostaining combined with hematoxylin and eosin counterstaining of failing left ventricular tissue disclosed RLX immunoreactivity in myocytes and interstitial cells (Fig. 4) . Myocytes disclosed a discrete granular pattern of staining that corresponds well with the results reported for the corpus luteum and endometrium (19) . Interstitial cells appeared more homogeneously stained. A) Western blot analysis shows myocardial expression of proRLX (ϳ18 kDa). ProRLX levels are higher in failing (F) than in nonfailing (NF) right atria and unchanged in failing ventricles. Exogenous H1 and H2 RLX (positive control; H1, 100 ng; H2, 500 ng) are also detected, but tissue levels of mature RLX were below the sensitivity of this analysis. Expression levels were normalized to ␣-actin (38 kDa). Quantitation is indicated for the different bands as fold activity compared with the mean of controls. B) Expression of prohormone convertase-1 (PC-1) mRNA in right atria and left ventricles, with failing myocardium exhibiting decreased atrial and a broad range of ventricular levels of the enzyme. The occurrence of RLX-like immunoreactivity was also confirmed by immunofluorescence in freeze sections. A granular fluorescence pattern was observed not only in the myocardium, but also in arterial and venous sections obtained from patients with CHF secondary to ischemic heart disease. In the vessels, however, the fluorescence usually appeared less evenly distributed.
Up-regulation of RLX expression by elevated filling pressure
We tested the hypothesis that myocardial dilatation corresponding to elevated filling pressures may constitute a key event in the regulation of RLX (Fig. 5) . Baseline values and time course of heart rate and coronary flow did not differ between these groups (data not shown). We established that an elevated LVEDP caused marked up-regulation of RLX gene expression compared with normal values. In contrast, elevation of both right and left atrial pressures had no effect on the expression of RLX mRNA (data not shown for left atria).
Sequencing of the PCR product verified that rat prepro-RLX cDNA had been amplified.
Relaxin inhibits stimulated ET-1 secretion
We recently demonstrated that pulmonary circulation represents a major site of ET-1 net release in patients with severe CHF (10) . ET-1, in turn, represents one of the most powerful mediators of CHF progression (20) . We therefore investigated whether RLX may affect pulmonary endothelial mechano-transduction leading to enhanced ET-1 expression, since such an effect would suggest a relevant neurohumoral role for RLX in the course of CHF. In a flow chamber model, we subjected pulmonary artery endothelial cells to hemodynamic conditions that mimic the in vivo situation of left ventricular failure with consequent pulmonary congestion [low arterial shear stress, ϭ18 dyn/cm 2 , and high downstream pressure at chamber outlet ('pulmonary wedge pressure'), Pϭ30 mm Hg]. Here we found a doubled ET-1 secretion over 16 h compared with normal hemodynamic constellations (ϭ30 or 50 dyn/ cm 2 , Pϭ10 mm Hg) (Fig. 6A) . This increase in peptide secretion corresponded to elevated preproET-1, endothelin-converting enzyme-1 (ECE-1), and ECE-2 mRNA levels (data not shown). At 5 nM, exogenous H2 RLX completely suppressed this hemodynamically induced increase in ET-1 secretion (Fig. 6A) , which can be ascribed to suppression of ET-1 gene expression (data not shown). The activity of human RLX in bovine endothelial cells also suggests that these cells express a functional RLX receptor. This RLX-receptor interaction apparently is not species-restricted, which has also been reported by others (1) .
In additional experiments, we tested the effects of exogenous H2 RLX on the AT-II-stimulated ET-1 secretion in pulmonary artery endothelial cells. This AT-IIinduced ET-1 secretion entails a well-established neurohumoral mechanism contributing to the progression of CHF (21) . Whereas ET-1 release is approximately doubled over 4 h and 8 h in the presence of 100 nM AT-II (which corresponds to elevated levels of mRNA encoding preproET-1 and ET-converting enzymes 1 and 2), 10 nM of RLX profoundly inhibits this increase in ET-1 secretion (Fig. 6B) . At the functional level, selective blockade of ET B receptors (representing the clearance site for ET-1; ref 22 ) by A-192621 completely prevents the inhibitory action of RLX-2 vis-a-vis ET-1. This phenomenon suggests an ET B receptor-mediated mechanism of the RLX effect, which was confirmed by detection of a massive increase in ET B receptor gene expression in the presence of AT-II plus RLX (Fig. 6C) .
Altogether, RLX exhibits a strong potential for in vitro suppression of stimulation in the ET-1 system. This finding led us to examine the in vivo correlation between plasma ET-1 and RLX in our patients.
Inverse correlation between plasma ET-1 and RLX in severe heart failure In Fig. 6D , we depict the significant inverse correlation between circulating ET-1 and RLX in tested patients suffering from severe CHF (quadratic regression, rϭ0.81, Pϭ0.008; linear regression, rϭ0.71, Pϭ0.013). Thus, individuals demonstrating the highest RLX plasma levels manifest the lowest circulating ET-1 concentrations in this group of patients. In patients with moderate CHF and in controls, we were not able to establish such a correlation (data not shown).
DISCUSSION
Known for many years as a hormone of human reproduction (6, 7), the polypeptide RLX has attracted more general attention since the early 1990s, when new studies revealed the remarkable pleiotropy of this mediator in rodents (4, 8) . In the present study, we offer the first evidence that 1) RLX is constitutively expressed in human cardiovascular tissues and 2) may play a relevant functional role in human heart failure. This evidence is based on the following. Plasma levels of RLX in patients increase profoundly with the severity of CHF, and they respond to acute hemodynamic improvement in the course of intensive care therapy. In severe CHF, we were able to detect net coronary release of RLX in more than 75% of the patients studied, which suggests the heart is a relevant source of elevated circulating RLX in human CHF. Moreover, we show for the first time that H1 and H2 gene expression can be detected in the heart and vessels among patients with preserved heart function as well as in patients suffering from CHF. The occurrence of CHF, however, is accompanied by significant elevation in myocardial H1 and H2 mRNA levels. Western blot analysis and immunostaining revealed translation of RLX mRNA into the RLX polypeptide in the heart and vessels.
We present novel findings in this study indicating expression of the proRLX processing enzyme (PC-1) in the heart and vessels. The differential PC-1 mRNA expression observed in failing atria and ventricles may explain the distinct pattern of proRLX protein levels: with H1 and H2 transcripts being elevated at both sites, decreased atrial expression of PC-1 may facilitate pro-RLX increase, whereas the nonuniform ventricular regulation of PC-1 may result in varying levels of proRLX. From immunostaining, myocytes and interstitial cells appear as the myocardial sources of RLX. At the functional level, myocardial dilation due to increased left ventricular filling pressure constitutes a regulatory event for RLX gene expression. Moreover, exogenous RLX was shown to effectively suppress the pulmonary endothelial ET-1 response to hemodynamic and humoral (AT-II) stimuli. RLX modulates AT-II effects, indicated by the increase of endothelial ET B receptor expression in the presence of AT-II plus RLX. The potential impact of these in vitro findings was accentuated by the data documented in our patients with severe CHF: circulating RLX shows a close inverse correlation with plasma ET-1, the most potent vasoconstrictor in heart failure and a powerful mediator of salt-retention and myocardial remodeling (20) .
From our findings and from the body of data obtained by investigating the effects of exogenous RLX in rodents, we may predict that the peptide chiefly exerts compensatory effects in the course of CHF: i.e., vasodilation (8) , diuresis caused by attenuation of the renal vascular response to AT-II (23) , stimulation of atrial natriuretic peptide (24) , collagen matrix degradation (25) , prevention of coronary thrombotic events by up-regulating tissue plasminogen activator (26) modulation of AT II effects, and suppression of the ET-1 system. In conclusion, we have identified a potential new player in human heart failure. Relaxin may prove valuable in assessing the prognosis of heart failure and represents a potential target for future therapeutic strategies.
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